DrugPatentWatch Database Preview
Glaxosmithkline Cons Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for GLAXOSMITHKLINE CONS, and what generic alternatives to GLAXOSMITHKLINE CONS drugs are available?
GLAXOSMITHKLINE CONS has fourteen approved drugs.
There are ten US patents protecting GLAXOSMITHKLINE CONS drugs.
There are two hundred and eighty-three patent family members on GLAXOSMITHKLINE CONS drugs in forty-three countries and twenty-three supplementary protection certificates in fourteen countries.
Summary for Glaxosmithkline Cons
| International Patents: | 283 |
| US Patents: | 10 |
| Tradenames: | 10 |
| Ingredients: | 9 |
| NDAs: | 14 |
| PTAB Cases with Glaxosmithkline Cons as petitioner: | See PTAB cases with Glaxosmithkline Cons as petitioner |
Drugs and US Patents for Glaxosmithkline Cons
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Cons | LAMISIL | terbinafine | GEL;TOPICAL | 020846-001 | Apr 29, 1998 | DISCN | No | No | Start Trial | Start Trial | |||||
| Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077658-001 | Jun 19, 2007 | DISCN | No | No | Start Trial | Start Trial | |||||
| Glaxosmithkline Cons | NICORETTE | nicotine polacrilex | TROCHE/LOZENGE;ORAL | 022360-001 | May 18, 2009 | OTC | Yes | No | 8,940,772 | Start Trial | Y | Start Trial | |||
| Glaxosmithkline Cons | LAMISIL AT | terbinafine hydrochloride | SPRAY;TOPICAL | 021124-002 | Mar 17, 2000 | OTC | Yes | Yes | Start Trial | Start Trial | |||||
| Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | 9,320,862 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Glaxosmithkline Cons
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Cons | EXCEDRIN (MIGRAINE) | acetaminophen; aspirin; caffeine | TABLET;ORAL | 020802-001 | Jan 14, 1998 | 4,943,565 | Start Trial |
| Glaxosmithkline Cons | LAMISIL AT | terbinafine hydrochloride | SOLUTION;TOPICAL | 021124-001 | Mar 17, 2000 | 6,121,314*PED | Start Trial |
| Glaxosmithkline Cons | LAMISIL | terbinafine | GEL;TOPICAL | 020846-001 | Apr 29, 1998 | 5,856,355*PED | Start Trial |
| Glaxosmithkline Cons | ALLI | orlistat | CAPSULE;ORAL | 021887-001 | Feb 7, 2007 | 4,598,089 | Start Trial |
| Glaxosmithkline Cons | LAMISIL AT | terbinafine | GEL;TOPICAL | 021958-001 | Jul 24, 2006 | 5,681,849*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE CONS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 60 mg | ➤ Subscribe | 2010-09-08 |
| ➤ Subscribe | Gum | 4 mg | ➤ Subscribe | 2013-01-22 |
| ➤ Subscribe | Gum | 2 mg | ➤ Subscribe | 2013-01-22 |
International Patents for Glaxosmithkline Cons Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Norway | 338929 | Start Trial |
| Japan | 2006502172 | Start Trial |
| Japan | 2007528248 | Start Trial |
| Hungary | E031175 | Start Trial |
| Russian Federation | 2458692 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Glaxosmithkline Cons Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0129748 | 98C0042 | Belgium | Start Trial | PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729 |
| 1305329 | CA 2008 00022 | Denmark | Start Trial | |
| 2506844 | 18C1022 | France | Start Trial | PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117 |
| 2506844 | 2018C/022 | Belgium | Start Trial | PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
| 2506844 | LUC00077 | Luxembourg | Start Trial | PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
